

MEMO
Pharmaceutical R&D - Rahway

TO: Tim Rhodes

FROM: Leigh Shultz

CONTRIBUTORS: Chris Lindemann
Dina Zhang
Robert Wenslow
James Qin
Peter Dormer
Leonardo Allain
Kari Lynn
Todd Gibson
Feng Li

SUBJECT: L-000224715 Preformulation Report

DATE: 30 Sep 2002

L-000224715 is a DP-IV inhibitor for the treatment of Type II Diabetes Mellitus. It was approved for development as a PCC by SARC in January of 2002 and began Phase I clinical trials in July 2002. This memo describes the chemical and physical properties of the compound known to date.

cc: Dept. 854, A. Andrews, J. Armstrong, R. Franklin, J. Givand, K. Hansen, W. Hunke, P. Hurter, D. Ip, D. Kim, K. Kube, G. Kwei, G. Lankas, E. Luna, K. Lynn, N. Margaretten, D. Mendenhall, M. Moonis, D. Ostovic, S. Palkar, J. Pearson, S. Reynolds, I. Santos, S. Shelukar, C. Starbuck, M. Thien, N. Thornberry, R. Tillyer, E. Tsai, S. Vincent, A. Weber, J. Wyvrat, D. Zhang, J. Zimmerman

Table of Contents

1.0 SUMMARY 3

2.0 DESCRIPTION 3

 2.1 NAME, STRUCTURE, FORMULA 3

 2.2 COLOR, FORM, APPEARANCE 3

3.0 TEST SUBSTANCES 3

4.0 PHYSICAL CHARACTERIZATION 4

 4.1 MICROSCOPY 4

 4.2 DIFFERENTIAL SCANNING CALORIMETRY (DSC) 6

 4.3 THERMOGRAVIMETRIC ANALYSIS (TGA) 7

 4.4 X-RAY POWDER DIFFRACTION (XRPD) 8

 4.5 SOLID STATE NMR (SSNMR) 9

 4.6 CRYSTAL FORMS/POLYMORPHISM 10

 4.7 HYGROSCOPICITY 13

 4.8 EQUILIBRIUM SOLUBILITY IN AQUEOUS MEDIA 15

 4.9 EQUILIBRIUM SOLUBILITY IN ORGANIC MEDIA 15

 4.10 pKA 16

 4.11 DISSOLUTION AND SOLUTION PROPERTIES 16

 4.12 UV/VIS ABSORBANCE SPECTRUM 16

5.0 STABILITY 17

 5.1 BULK DRUG STABILITY 17

 5.2 SOLUTION STABILITY 18

 5.3 MODES OF DEGRADATION 19

6.0 ANALYTICAL METHODS 20

 6.1 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY 20

 6.2 HPLC/MS/MS 20

 6.3 UV/VIS ABSORBANCE 20

 6.4 SOLID-STATE NMR 21

7.0 BIOPHARMACEUTICAL PROPERTIES 22

8.0 BULK DRUG FORM/DOSAGE FORM DESIGN CONSIDERATIONS 24

9.0 MECHANICAL PROPERTIES 25

 9.1 BULK DRUG CHARACTERIZATION 25

1.0 SUMMARY

This memo summarizes the preformulation data available for the single known polymorphic form of the crystalline monobasic phosphate salt of L-000224715. The phosphate salt is a stable, high-melting, non-hygroscopic material with known isomorphous solvates. It is highly soluble in aqueous media across the physiological pH range and has adequate stability in solution below pH 6. The flow properties of the phosphate salt are good, suited to a direct compression formulation.

2.0 DESCRIPTION

L-000224715, a DP-IV inhibitor, is being developed for oral administration as a treatment for type II (adult-onset) Diabetes Mellitus. This compound is the second DP-IV inhibitor in development at Merck.

2.1 Name, Structure, Formula

L-000224715 has a molecular weight of 407.32 g/mol and a molecular formula of $C_{16}H_{15}F_6N_5O$. It is being developed as the monobasic phosphate salt, with molecular weight 505.32 g/mol (salt factor 1.24) and molecular formula $C_{16}H_{18}F_6N_5O_5P$. The structure of L-000224715 is shown in Figure 1, below.




Figure 1. Structure of L-000224715

2.2 Color, Form, Appearance

The phosphate salt of L-000224715 is a white, crystalline powder with flake-like individual crystals. The powder shows some agglomeration and good flow properties.

3.0 TEST SUBSTANCES

All experiments were performed on lots of phosphate salt provided by Process Research. Stability, solubility, microscopy, particle sizing, XRPD, hygroscopicity, and thermal experiments were performed on lot L-000224715-006F006 (A-sheet). SEM data were obtained on lot L-000224715-006F007 (D-sheet). Particle size data are also shown for lots 006F003 (A-sheet) and 006F009 (A-sheet), which were used for assessing the feasibility of the Xcelodose*. Lots 006 and 007 came from the same chemical batch, which was split and released separately. Data obtained from other lots of phosphate salt are noted in the text. Both aqueous solubility as a function of pH and the pKa were determined with the crystalline free base, L-000224715-000T001.

4.0 PHYSICAL CHARACTERIZATION

4.1 Microscopy

Optical microscopy performed on lot L-000224715-006F006 at 200X magnification (Figure 2) reveals a birefringent, crystalline material. The primary crystals have a well-defined flake-like morphology; many of the flakes have a hexagonal shape. Some agglomeration of the crystals is observed.




Figure 2. Optical microscopic image of L-000224715-006F006 (200X)

SEM images of L-000224715-006F007 are shown in Figure 3. Agglomeration of the individual crystals is evident in these images.




Figure 3. SEM images of L-000224715-006F007, showing agglomeration (205X, left; 170X, right)

Q:\Dept_854\preformulationreports\L-224715PreformulationReport.doc

Figure 4 shows particle size data for three lots of L-000224715, obtained using a MicroTrac light-scattering instrument with isopropanol as the medium. Lot 006 shows a broad, monomodal particle size distribution with a mean of 79 μm after 30 s of sonication ($D_{10} = 23 \mu\text{m}$, $D_{95} = 190 \mu\text{m}$). Prior to sonication, the mean particle size was 113 μm , with a D_{10} of 27 μm and a D_{95} of 285 μm . The decrease in both D_{95} and the mean on sonication indicates the loose nature of the agglomerates shown in Figure 3. Lots 003 and 009, used for testing the feasibility of the Xcelodose^{*}, have similar average particle sizes, but show less agglomeration, decreasing from mean particle sizes of 46 and 65 μm , respectively, to 42 and 56 μm on sonication.




Figure 4. Comparison of particle size distribution for L-000224715-006F003, -006F006, and 006F009

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.